Vanda Pharmaceuticals, ‘Hetlioz’, drug to to treat non-24-hour sleep-wake disorder receives FDA’s nod

On January 31, 2013, The U.S Drug and Food Administration (FDA) approved Hetlioz (tasimelteon) to treat non-24-hour sleep-wake disorder in totally blind individuals. Hetlioz works as a melatonin receptor agonist that binds to and activates melatonin receptors within the brain. Non-24-hour sleep-wake disorder (“non-24”) is a chronic circadian rhythm disorder in the blind that causes … Continue reading Vanda Pharmaceuticals, ‘Hetlioz’, drug to to treat non-24-hour sleep-wake disorder receives FDA’s nod